POSITIVE RESULTS FROM PHASE 1B STUDY OF PHOSPHAGENICS’ TRANSDERMAL OXYCODONE PATCH

Transdermal oxycodone represents a significant advance in the treatment of chronic pain; Phosphagenics aims to become the first company to offer an oxycodone patch that will provide sustained pain relief

Phosphagenics Limited (“Phosphagenics”) (ASX: POH; OTCQX: PPGNY) today announced positive results from a Phase 1b clinical study using the Company’s patented TPM™  (Targeted Penetration Matrix) for the transdermal delivery of oxycodone.  This successful trial showed that daily application of a TPM™-oxycodone patch delivered therapeutic bloodstream levels of oxycodone in a reproducible, consistent and sustained manner.

3 February 2010

PHOSPHAGENICS LAUNCHES AUSTRALIAN SKINCARE PRODUCTS

• Exclusive sales arrangement with Pulse Pharmacies, Vitamin Me and Roy Young stores nationally
• TPM technology is superior in delivering more active ingredients into the skin such as anti-ageing retinol

Phosphagenics Limited (ASX:POH, OTCQX:PPGNY) has signed an agreement appointing Pulse Pharmacies as its exclusive Australia-wide distributor of Phosphagenics’ new Elixia™ skincare product range.

NEWSLETTER - DECEMBER 2009
featuring the new Elixia range (refer to Personal Care Products under Nutraceuticals)


To view releases in full please click here